Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks told Bloomberg News on Monday that data on the drug, orforglipron ...
Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...
Eli Lilly expects ... data on the drug, orforglipron, by the middle of this year. Get top local stories in San Diego delivered to you every morning. Sign up for NBC San Diego's News Headlines ...
The new outlook would still mark a 32% jump in revenue from the prior year. Eli Lilly has been racing to meet soaring demand for its diabetes treatment Mounjaro and obesity drug Zepbound ...